Background There is concern about the potential of an increased risk related to medications
that act on the renin–angiotensin–aldosterone system in patients exposed to coronavirus …

Background A potential association between the use of angiotensin-receptor blockers
(ARBs) and angiotensin-converting–enzyme (ACE) inhibitors and the risk of coronavirus …

Background Concerns have been raised about the possibility that inhibitors of the renin–
angiotensin–aldosterone system (RAAS) could predispose individuals to severe COVID-19; …

Importance It has been hypothesized that angiotensin-converting enzyme inhibitors
(ACEIs)/angiotensin receptor blockers (ARBs) may make patients more susceptible to …

After initially hypothesizing a positive relationship between use of renin-angiotensin-
aldosterone system inhibitors and risk of coronavirus disease 2019 (COVID-19), more recent …

Background Angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor
blockers (ARBs) have been postulated to affect susceptibility to COVID-19. Observational …

Background and rationale Some studies of hospitalized patients suggested that the risk of
death and/or severe illness due to COVID-19 is not associated with the use of angiotensin …

Introduction The epidemic due to severe acute respiratory syndrome coronavirus 2 (SARS-
CoV-2) infection has been spreading globally, raising increasing concerns. There are …

It remains uncertain whether the hypertension (HT) medications angiotensin‐converting
enzyme inhibitors (ACEi) and angiotensin receptor blockers (ARB) mitigate or exacerbate …

Importance The chronic receipt of angiotensin-converting enzyme inhibitors (ACEIs) and
angiotensin receptor blockers (ARBs) has been assumed to exacerbate complications …